The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent.
wherein, a broken line means the presence or absence of a bond; R
1
is substituted or unsubstituted alkyl etc., R
2
is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R
3
is a substituted or unsubstituted aromatic carbocyclic group; R
4
is a hydrogen atom etc.; R
5
is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R
6
is substituted or unsubstituted alkyl; R
7
is —Z—R
71
etc.; Z is —NR
72
—CO— etc.; R
71
is substituted or unsubstituted alkyl etc.; R
72
is a hydrogen atom etc.
17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
申请人:Hartmann Rolf
公开号:US20100204234A1
公开(公告)日:2010-08-12
The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).